What is Stemgent?
Stemgent is dedicated to advancing stem cell research through the development of innovative technology and application solutions. Collaborating with leading stem cell scientists globally, the company aims to streamline cellular reprogramming research. Its product offerings are designed by world-renowned stem cell researchers, making advanced tools accessible to the scientific community worldwide. Stemgent's focus on simplifying complex research processes positions it as a key player in the biotechnology landscape.
How much funding has Stemgent raised?
Stemgent has raised a total of $40.8M across 5 funding rounds:
Series A
$6.5M
Series B
$14M
Other Financing Round
$2.7M
Private Equity
$6.3M
Private Equity
$11.3M
Series A (2008): $6.5M with participation from Morgenthaler Private Equity and HealthCare Ventures
Series B (2009): $14M led by Frazier Healthcare Partners and Morgenthaler Private Equity
Other Financing Round (2009): $2.7M supported by Morgenthaler Private Equity and HealthCare Ventures
Private Equity (2012): $6.3M featuring HealthCare Ventures LLC
Private Equity (2012): $11.3M backed by HealthCare Ventures LLC
Key Investors in Stemgent
HealthCare Ventures LLC
HealthCare Ventures is a leading life science venture capital firm investing in pre-clinical or early clinical stage, focused companies with potential to transform patient care.
Morgenthaler Private Equity
Morgenthaler is a premier venture capital and private equity firm with over 40 years of experience in creating valuable companies. They specialize in investments in the Information Technology and Life Sciences sectors.
Frazier Healthcare Partners
Phathom Pharmaceuticals is a late clinical-stage biopharmaceutical company focused on developing and commercializing new treatments for GI disorders. Frazier Healthcare Partners is a prominent investor in the healthcare sector.
What's next for Stemgent?
With substantial enterprise-level backing, Stemgent is poised for accelerated expansion and further technological development. The company's strategic investments suggest a focus on scaling its operations, enhancing its product pipeline, and potentially exploring new therapeutic applications derived from its stem cell technologies. Future endeavors will likely involve deepening collaborations with research institutions and expanding its global market reach, solidifying its role in the future of regenerative medicine.
See full Stemgent company page
